Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02114554
Other study ID # 201307058RINB
Secondary ID
Status Recruiting
Phase N/A
First received February 9, 2014
Last updated April 13, 2014
Start date January 2014
Est. completion date January 2015

Study information

Verified date April 2014
Source National Taiwan University Hospital
Contact Han-Chung Hsiue, MD
Phone 886-23123456
Email hanchunghsiue@gmail.com
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Observational

Clinical Trial Summary

Mitochondrial diseases are multisystem disorders that present with a wide range of clinical manifestations. Mitochondrial DNA nt3243A>G mutation is one of the most common mutations seen in mitochondrial diseases. Syndromes associated with this mutation include mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD), myoclonic epilepsy with ragged red fibers (MERRF), and chronic progressive external ophthalmoplegia (CPEO). Clinical analyses of mitochondrial DNA nt3243A>G mutation from Taiwan remain scarce. The present study aims to investigate the clinical features and prognostic factors of patients with mt3243A>G mutation in Taiwan.


Description:

Patients and clinical features. The study will be carried out at National Taiwan University hospital, a tertiary medical center in Taipei. The Medical Genetics Department at National Taiwan University Hospital receives referral and conducts genetic testing for hospitals all around Taiwan. We will review the medical chart of all patients with documented mitochondrial DNA nt3243 point mutation. Demographic data, age at onset of symptoms, clinical features (including stroke, seizure-like episode, lactic level, diabetes mellitus, hearing impairment, myopathy, electrocardiogram abnormality, chronic progressive external ophthalmoplegia), relevant family history, treatment, and outcome will be recorded. Full MELAS phenotype was defined as the presence of focal central nervous system events, either seizures, strokes, or both.

Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA purification kit (Gentra Systems, Minneapolis, Minnesota, USA). Polymerase chain reaction (PCR) for mitochondrial DNA nt3243 point mutation was carried out by left primer 5'-cggagtaatccaggtcggtt-3' and right primer 5'-ggaattgaacctctgactgt-3'. Presence of mitochondrial DNA nt3243 A>G mutation was detected after Hae III restriction enzyme digestion.

Heteroplasmy of mitochondrial nt3243A>G mutation was detected by real-time amplification refractory mutation system quantitative PCR (ARMS-qPCR) assay as previously reported [19]. In brief, wild-type and mutant-target primers, each 500 nM, were added into a 10-ml PCR reaction containing 1X KAPA SYBR® FAST ABI Prism® qPCR Master Mix (KAPABIOSYSTEMS, Cat No. KK4603) and 4 ng of genomic DNA. Real-time PCR conditions were 2 min at 50°C, 20 seconds at 95°C, followed by 40 cycles of 15 seconds of denaturation at 95°C and 30 seconds of annealing/extension at 62°C. Data of cross point and concentration fluorescent signal intensity of PCR products was recorded and analyzed by ABI StepOnePlusTM Real-Time PCR System (Applied Biosystems) and StepOne software v2.1 (Applied Biosystems). The threshold cycle ( CT value) within the linear exponential phase was used to construct the standard curve and to measure the original copy number of DNA template. The percentage of the mutant mtDNA was calculated using formula as below: Heteroplasmy %= 1/(1+ 1/2△CT).

Statistical analysis. SPSS 17.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Results were given as median and range, or mean ± 1 SD, when appropriate. Student 's t-test was used to compare unpaired groups. Fisher's exact test was used to determine associations between two categorical variables. Cox-regression model was used to analyze possible prognostic factors. Inter-group differences at outcome were compared by Kaplan-Meier estimate and log-rank test. Pearson's correlation was used to correlate heteroplasmy to age of diagnosis. A p value < 0.05 was considered statistically significant.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

-Patients with mitochondrial DNA nt3243 A>G mutation

Exclusion Criteria:

-Patients without confirmed mitochondrial DNA nt3243 A>G mutation

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital National Cheng-Kung University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prognostic factors for poor outcome Poor outcome includes death and development of poor performance (a modified Rankin scale 4 or higher). Univariate and multivariate analyses will be utilized to study whether specific clinical presentations (for instance, the presence of stroke, seizure, diabetes, etc.) and degree of heteroplasmy are associated with poor outcome. Within follow-up period, which is estimated to be 5 years in average. No
See also
  Status Clinical Trial Phase
Completed NCT01831934 - Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS) Phase 4
Not yet recruiting NCT06013397 - Effectiveness of Ketogenic Diet in MELAS Syndrome N/A
Completed NCT04165239 - The KHENERGYZE Study Phase 2
Completed NCT01603446 - L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome Phase 2
Completed NCT00887562 - Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes Phase 2
Active, not recruiting NCT00068913 - Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome Phase 2
Completed NCT03888716 - A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease Phase 1
Completed NCT04948138 - Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome N/A
Completed NCT03056209 - Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers Phase 1
Completed NCT01339494 - Nitric Oxide Production in MELAS Syndrome Phase 0
Active, not recruiting NCT05255328 - Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome N/A
Recruiting NCT05554835 - Global Registry and Natural History Study for Mitochondrial Disorders
Completed NCT01252979 - Ketones & Mitochondrial Heteroplasmy Phase 0
Completed NCT00004353 - Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia N/A
Recruiting NCT03952234 - L-Citrulline Dose Finding Safety Study in MELAS Phase 1